Innovative use of therapeutic antibodies in lung cancer: the current landscape of ADCs and other antibody-based therapies

Matthew Lee, Christine M. Lovly

Open source

DOI
10.3389/fonc.2026.1814095
Published
2026-07-08
Container
Frontiers in Oncology
Publisher
Frontiers Media SA
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2026.1814095,
  title = {Innovative use of therapeutic antibodies in lung cancer: the current landscape of ADCs and other antibody-based therapies},
  author = {Matthew Lee and Christine M. Lovly},
  year = {2026},
  journal = {Frontiers in Oncology},
  doi = {10.3389/fonc.2026.1814095},
  url = {https://doi.org/10.3389/fonc.2026.1814095}
}

RIS

TY  - JOUR
TI  - Innovative use of therapeutic antibodies in lung cancer: the current landscape of ADCs and other antibody-based therapies
AU  - Matthew Lee
AU  - Christine M. Lovly
PY  - 2026
JO  - Frontiers in Oncology
DO  - 10.3389/fonc.2026.1814095
UR  - https://doi.org/10.3389/fonc.2026.1814095
ER  - 

APA

Lee, M., & Lovly, C. M. (2026). Innovative use of therapeutic antibodies in lung cancer: the current landscape of ADCs and other antibody-based therapies. Frontiers in Oncology. https://doi.org/10.3389/fonc.2026.1814095

Source records